MorphoSys to Present Data on Proprietary Programs at ASCO Annual Meeting
News May 26, 2015
MorphoSys AG has announced the publication of three MorphoSys abstracts which were submitted to the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting to take place from May 29 to June 2 in Chicago, Illinois.
The abstracts include pre-clinical and first clinical data on the Company's proprietary drug candidate MOR202 from a Phase 1/2a study in patients with multiple myeloma and updated clinical data for the MOR208 program.
"We are delighted to publish a substantial package of clinical and preclinical data at the preeminent conference on clinical oncology. The data set provides additional insight into the progress of our lead cancer compounds MOR208 and MOR202," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "For MOR202, we are in particular looking forward to presenting not only safety data but also first efficacy data from the Phase 1/2a study in multiple myeloma."
List of abstracts:
A phase 1/2a study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM).
The poster presentation will include in the abstract described safety results and additional first efficacy results. The poster presentation will take place on Sunday, May 31, 8:00 AM - 11:30 AM CDT, as part of the Lymphoma and Plasma Cell Disorders track.
Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.
The poster presentation will take place on Sunday, May 31, 8:00 AM - 11:30 AM CDT, as part of the Lymphoma and Plasma Cell Disorders track.
Phase 2a study of single-agent MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
The oral presentation will take place Monday, Jun 1, 9:45 AM - 9:57 AM CDT, as part of the Lymphoma and Plasma Cell Disorders track.
Additionally, MorphoSys's partners will present data for several HuCAL antibodies, which are currently in clinical development:
A phase I study of PF-05082566 (anti-4-1BB) + rituximab in patients with CD20+ NHL.
Phase 1 study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
Final results of phase 1b of tarextumab (TRXT, OMP-59R5, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC).